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Abstract
A-Raf kinase can inhibit apoptosis by binding to the pro-apoptotic MST2 kinase. This function
relies on expression of hnRNP H, which ensures the correct splicing of a-raf mRNA needed to
produce full-length A-Raf protein. Here we show that expression of hnRNP H and production of
full-length A-Raf is positively controlled by c-Myc. Low c-Myc reduces hnRNP H expression and
switches a-raf splicing to produce A-Rafshort, a truncated protein. Importantly, A-Rafshort fails to
regulate MST2 but retains the Ras binding domain such that it functions as a dominant negative
mutant suppressing Ras activation and transformation. Human colon and head and neck cancers
exhibit high hnRNP H and high c-Myc levels resulting in enhanced A-Raf expression and reduced
expression of ARafshort. Conversely, in normal cells and tissues where c-Myc and hnRNP H are
low, A-Rafshort suppresses ERK activation such that it may act as a safeguard against oncogenic
transformation. Our findings offer a new paradigm to understand how c-Myc coordinates diverse
cell functions by directly affecting alternate splicing of key signaling compotents.
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Introduction
The family of Raf protein kinases, which comprises A-Raf, B-Raf, and Raf-1, is at the apex
of the three-tiered Raf-MEK-ERK/MAPK pathway that regulates many fundamental cellular
functions, including proliferation, differentiation, transformation, apoptosis and metabolism
(1). Raf kinase activation is initiated by binding to activated Ras GTPases at the cell
membrane, which triggers a complex series of activation events that comprise interactions
with proteins and lipids as well as coordinated de-phosphorylation and phosphorylation
events (2, 3). A-Raf is the least studied member of the Raf kinase family (4). In general, A-
Raf seems to be regulated similar to Raf-1, with binding to activated Ras initiating the
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growth factor induced activation of A-Raf. However, A-Raf is a poor MEK kinase with
barely measurable catalytic activity, which is due to unique non-conserved amino acid
substitutions in the N-region (5). Independent of kinase activity, A-Raf constitutively binds
mammalian sterile 20-like kinase (MST2) and suppresses MST2 activation and induced
apoptosis (6).
The ERK pathway is frequently activated in cancer, often due to activating mutations in Ras
(7, 8) or B-Raf (9, 10). By contrast, Raf-1 is rarely mutated (11), and to date no oncogenic
A-Raf mutations were found. However, elevated A-Raf expression levels have been
observed in a number of malignancies including astrocytomas (12), pancreatic ductal
carcinoma (13), angioimmunoblastic lymphadenopathies (14), head and neck squamous cell
carcinomas, and colon carcinomas (6, 15).
One way to regulate protein expression and activity is alternative splicing. For B-Raf several
different splice forms are known. Two variable exons, 8b and 10, allow for the generation of
four distinct isoforms (16, 17). While the presence of exon 10 enhances the basal kinase
activity and affinity to MEK, exon 8b has the opposite effect (16). Thyroid carcinomas
express B-Raf splice variants that lack the N-terminal auto-inhibitory domain resulting in
constitutively active B-Raf variants, suggesting that alternative splicing regulation is a
pathophysiological mechanism for oncogenic B-Raf activation (18). An alternative Raf-1
splice form lacking exon 3 was reported in lung cancer, however the functional
consequences are unknown (19). Recently, two alternative murine A-Raf splice forms were
described, DA-Raf1 and DA-Raf2, which contain the Ras binding domain (RBD) but lack
the kinase domain due to pre-terminal stop codons (20, 21). DA-Raf1 and DA-Raf2 bind to
activated Ras, but due to the lack of a kinase domain cannot transduce a signal and act as
dominant-negative antagonists of the Ras-ERK pathway. Thus, DA-Raf1 is a positive
regulator of myogenic differentiation by inhibiting activation of the ERK pathway (20). In
another cellular environment, DA-Raf2 binds and colocalizes with the ARF6 GTPase on
tubular endosomes and acts as dominant negative effector of endocytic trafficking (21). We
recently reported that expression of the full length A-Raf protein requires the expression of
the splice factor hnRNP H, which is upregulated in several tumours including colon and
head and neck cancers (6, 15) We showed that hnRNP H upregulation ensures the
expression of the mature a-raf mRNA thus allowing the sufficient production of full-length
A-Raf protein to counteract MST2-mediated apoptosis.
Here, we report that hnRNP H is a direct transcriptional target of c-Myc, which stimulates
its expression. The proto-oncogenic transcription factor c-Myc is a key regulator of various
cellular processes such as cell growth, proliferation, apoptosis, and differentiation (22, 23).
Recent studies suggest that c-Myc regulates about 15% of all annotated genes by direct
transcriptional activation (24, 25). Deregulated and elevated expression of c-myc has been
shown for a wide range of cancers and it is estimated that c-Myc is involved in 20% of all
human cancers (26). We show that hnRNP H maintains the expression of full-length A-Raf
protein by suppressing alternative splicing of the a-raf mRNA. This novel splice form, A-
Rafshort, incorporates intronic sequences, and generates a 171 amino acid protein, which
lacks the kinase domain. While A-Rafshort fails to regulate MST2-mediated apoptosis, it is a
potent inhibitor of ERK signaling and cellular transformation by binding and blocking
activated Ras. A-Rafshort expression levels were reduced in several cancer entities,
suggesting that A-Rafshort acts like a tumour suppressor protein in these tumours.
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Materials and Methods
Cell lines
HeLa, GHD-1, HCT116, and NIH3T3 cells were cultured in standard DMEM containing
10% fetal calf serum (FCS). Cell lines were either purchased from Cancer Research UK or
ATCC and were authenticated by the European Collection of Cell Cultures (ECACC).
GHD-1 is a self-established cell line from a hypopharynx HNSCC tumour (27).
Transfections
Transient transfections were conducted with Lipofectamine 2000 reagent (Invitrogen,
Paisley, UK) or the Nucleofector system (Lonza Cologne, Cologne, Germany) according to
the manufacturers’ instructions.
Focus Assays
Focus assays were conducted as described previously (28). Briefly, NIH 3T3 cells were
transfected with Lipofectamine (Invitrogen) and allowed to grow to confluence. The plates
were incubated for 12-15 days. Then, cells were fixed, stained with Giemsa, and the foci
were counted.
Semi-quantitative RT-PCR
RNA from human tissues was isolated using the Precellys 24 cell lysis system (Bertin
Technologies, Montigny-le-Bretonneux, France). Total RNA from tissues and cell lines was
isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany and cDNA was generated
using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Paisley, UK)
according to the manufacturers’ instructions.
Immunoprecipitations
Immunoprecipitations were conducted as described previously (6) with the following
immobilized antibodies: Monoclonal mouse anti-HA tag antibody 3F10 (Roche Diagnostics,
Mannheim, Germany), monoclonal mouse anti-flag antibody M2 (Sigma, Taufkirchen,
Germany), polyclonal goat anti-human MST2 antibody sc-6211 (Santa Cruz, Santa Cruz,
US), monoclonal mouse anti-human Ras antibody sc-29 (Santa Cruz, Santa Cruz, US).
MST2-kinase activity assay
MST2 kinase activity was measured by in-gel assays as described before (29).
Apoptosis assays
Apoptosis was determined as described previously (6) by measuring subgenomic DNA.
Statistical analysis
Significance levels were determined by two-tailed Student t-test analyses. Due to the non-
normal distribution of the expression analysis data (RT-PCR), results are given as the
median with the interquartile range (IQR). For comparison of hnRNP H and A-Raf isoform
expression between sample groups, we used the Wilcoxon signed-rank test. All tests were
two-sided and results considered significant if p<0.05.
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Results
HnRNP H regulates A-Raf isoform selection
We reported recently, that the splice factor hnRNP H is necessary for the proper expression
of the mature A-Raf mRNA (6). Here we show that, when hnRNP H is depleted a novel,
alternatively spliced A-Raf mRNA species appears at the expense of the mature mRNA.
Depletion of hnRNP H decreased the levels of mature A-Raf mRNA and full-length protein
levels, while causing the appearance of a new mRNA species, which yielded a larger PCR
product (Fig. 1A). Sequencing revealed that introns two and four of the a-raf gene were
included while introns one and three were spliced out (Figure S1 and S2). This alternative a-
rafshort mRNA encodes 171 amino acids that are only partially related to the A-Rafwt protein
sequence due to the intronic inclusions. PANTHER database entries for the full-length
generic and the alternative mRNAs/proteins are hCT20300/hCP44398 and hCT2257035/
hCP1885829, respectively. The cognate A-Rafshort protein lacks the C-terminal two-thirds
of A-Rafwt including the kinase domain because of the presence of a stop codon at
nucleotide position 716 in intron 4 (Fig. S2). Pre-terminated mRNAs are commonly prone to
nonsense-mediated decay (32). However, endogenous A-Rafshort protein was detectable
(Fig. 1B) suggesting a physiological function for A-Rafshort. Furthermore, downregulation
of hnRNP H caused a reduction in the expression of the full length A-Rafwt protein with a
concomitant increase in the expression of the A-Rafshort protein (Fig. 1B), confirming the
results of the mRNA expression at the protein level. Pre-incubation of primary antibodies
with the A-Rafshort peptide used for immunisation resulted in a complete loss of detection by
the A-Rafshort-, but not by the HA-specific antibody (Fig. 1C).
Alternative splice variants of a-raf differ in function
Full-length A-Raf prevents apoptosis by sequestering and inactivating the proapoptotic
kinase MST2 (6). In contrast, A-Rafshort did not interact with flag-tagged MST2 or
endogenous MST2 (Figs. 2A,B). Consequently, A-Rafshort was neither able to suppress
endogenous MST2 kinase activity (Fig. 2C), nor apoptosis in response to hnRNP H knock-
down, as measured by the percentage of cells with a subG1 DNA content, the cleavage of
PARP and caspase 3 (Fig. 2D).
A-Rafshort negatively regulates the Ras-ERK pathway
The truncated A-Rafshort contains the Ras-binding domain (RBD) including novel amino
acids derived from intronic sequences but lacks the S/T rich domain and the kinase domain.
This structure suggested that A-Rafshort might act as dominant-negative Ras antagonist.
Overexpression of A-Rafshort in HeLa, GHD-1, and HCT116 cancer cells (Fig. 3A), reduced
cell numbers (Fig. 3A), possibly by inhibition of Ras-ERK signalling. In serum-stimulated
HeLa cells overexpression of A-Rafshort leads to a decrease in pERK levels 3-fold while
having no effect in quiescent cells (Fig. 3B-C, Fig. 4A). In contrast, phosphorylation levels
of Akt were unchanged after A-Rafshort overexpression (Fig. 3C) suggesting that A-Rafshort
selectively antagonizes Ras-ERK signalling leaving Ras-PI3K-Akt signalling unaffected.
While increased expression of A-Rafshort led to a decrease in ERK activity, depletion of A-
Rafshort using an isoform-specific siRNA had the opposite effect, i.e. increasing activating
phosphorylation levels of ERK (Fig. 3D). In serum-stimulated HeLa cells, knockdown of A-
Rafshort increased pERK by 30%, while having no effect in quiescent cells (Fig. 3D).
A-Rafshort interacts with Ras and antagonises Ras transformation
In order to act as a Ras antagonist, A-Rafshort should interact with activated Ras. We
transfected HeLa cells with A-Rafshort or full length A-Raf (A-RafWT) and performed co-
immunoprecipitations showing that both proteins interact with Ras in serum-stimulated cells
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(Fig. 4A). The same results were obtained with endogenous A-Rafshort and Ras (Fig. 4B).
Furthermore, experiments where different amounts of A-Rafshort and A-RafWT were co-
transfected, showed that A-Rafshort efficiently competes with A-RafWT for binding to
activated Ras (Fig. 4C). These data confirm that A-Rafshort acts as a physiological negative
regulator of Ras-ERK signalling.
Oncogenic Ras is a well-described activator of Ras-mediated ERK signalling and induces
transformation in mouse fibroblasts (33, 34). As A-Rafshort interacted with activated Ras,
and abrogated ERK activation, we asked whether oncogenic Ras-induced transformation
was inhibited by A-Rafshort. NIH3T3 cells were transfected with activated Ras mutants (H-
RasV12, K-RasV12, N-RasV12) and co-transfected with A-Rafshort and tested for the ability
to generate foci of transformed cells (Fig. 4C,D). A-Rafshort significantly decreased foci
numbers with all three Ras isoforms suggesting that A-Rafshort can inhibit transformation by
all three Ras members. In order to prove that A-Rafshort is acting directly on Ras and not on
downstream effectors, NIH3T3 cells were co-transfected with A-Rafshort and the viral Raf
oncogene (vRaf), which lacks the Ras binding domain and transforms cells independently of
Ras (33). A-Rafshort had no significant effect on v-Raf induced foci numbers, showing that
A-Rafshort is inhibiting activated Ras and not the downstream kinase Raf (Fig. S3A, B). We
also tested whether the function of A-Rafshort differs from other known A-Raf splicing
isoforms. In colony formation assays, daRaf1 and daRaf2, like A-Rafshort, significantly
decreased foci numbers with all three Ras isoforms suggesting that these isoforms have
overlapping functions (Fig. S3C, D).
c-Myc regulates A-Raf isoform selection via hnRNP H
hnRNP H is over expressed in several carcinoma entities and regulates a-raf splicing (6). We
asked therefore, which process is responsible for the expression of hnRNP H. As hnRNP H
was found as a target gene of the proto-oncogene c-Myc in microarray experiments (24) we
tested this hypothesis experimentally in more detail. Depleting c-Myc from HeLa cells using
specific siRNAs reduced hnRNP H protein expression levels and, in parallel, decreased
levels of A-RafWT and increased levels of A-Rafshort (Figure 5A). Increased cell confluence
triggered a similar response, i.e. decreasing levels of c-Myc, hnRNP H, and A-RafWT while
increasing levels of A-Rafshort (Fig. S4). These results suggest that a concerted response of
c-Myc, hnRNP H and A-Raf isoform expression is part of the physiological programme how
cells respond to different growth conditions. To ascertain that this response was coordinated
by c-Myc, we transfected HeLa cells with MycERT (35). MycERT is a chimeric protein
where c-Myc is fused to a mutated ligand binding domain of the human estrogen receptor.
MycERT is retained in the cytoplasm due to the ER portion binding to Hsp90. Addition of
the estrogen analog 4-hydroxytamoxifen (4-OHT) releases MycERT and triggers its
translocation to the nucleus and activation of Myc-induced transcription. In the absence of
4-OHT, expression levels of hnRNP H, A-RafWT, and A-Rafshort were constant over a
timecourse of 8 hrs. Upon addition of 4-OHT, hnRNP H and A-RafWT levels increased,
while A-Rafshort expression decreased (Figure 5B). Additional knock-down of hnRNP H
using specific siRNAs abrogated this effect indicating that c-Myc is regulating A-Raf
isoform selection via control of hnRNP H expression. Endogenous activation of c-Myc by
EGF stimulation corroborated these results (Figure 5C). While expression levels of
hnRNPH, A-RafWT, and A-Rafshort remained stable in starved cells, activation of c-Myc led
to increased hnRNP H and A-RafWT expression, but decreased A-Rafshort expression.
Data from the ENCODE project (31) suggested, that c-Myc binds to three regions in the
HNRNPH1 promoter (Fig. S5). We could identify four putative, non-canonical E-Boxes
957bp (CATGTG), 949bp (CACATG), 530bp (CAGCTG), and 63bp (CAGCTG) upstream
of the transcription start site, which coincide with the ChIP-Chip data from ENCODE in six
different cell lines (Fig. S5). In order to determine direct interaction of c-Myc with the
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HNRNPH1gene we performed a chromatin immunoprecipitation (ChIP) analysis of the
human HNRNPH1 promoter. ChIP indicated that c-Myc was constitutively present at three
E-Boxes of the HNRNPH1 promoter region (957bp, 949bp, 530bp) in both serum-starved
and stimulated cells. However, c-Myc was recruited to the E-box nearest to the transcription
start site only in stimulated cells (Fig. 5D). Collectively, our results show that hnRNP H is a
direct target of the proto-oncogene c-Myc and that c-Myc regulates the ERK pathway via
hnRNP H and subsequent regulation of A-Raf isoform expression.
The A-Rafshort isoform is downregulated in carcinomas
The expression of the proto-oncogene c-Myc is elevated in a plethora of human tumours
(22). Additionally, hnRNPH and A-RafWT were shown to be overexpressed in several
carcinoma entities including head and neck carcinomas and colon carcinomas (6). Therefore,
we asked if A-Rafshort and other A-Raf isoforms are regulated during carcinogenesis and
whether their expression is dependent on the expression of the upstream regulators c-Myc
and hnRNP H. To this end, endogenous mRNA expression levels of c-myc, hnrnph, a-rafwt,
and a-rafshort were analysed in a series of human head and neck carcinomas (T, n=17) and
adjacent non-malignant tissues (N, n=14) by semi-quantitative RT-PCR (Fig. 6A). At the
single-patient level, a median relative expression of 2.3-fold for c-myc, 1.7-fold for hnrnph,
1.5-fold for a-rafwt, and 0.5-fold for a-rafshort in tumour specimens was calculated,
indicating that c-myc, hnrnph and a-rafwt are over expressed in carcinomas. In contrast, a-
rafshort appears to be downregulated in tumours.
Additionally, after stratifying patients according to their relative expression levels of c-myc,
hnRNP H, a-rafwt, and a-rafshort mRNA in tumour tissue, a significant number of patients
showed high expression of c-myc (χ2=7.0, p=0.082), hnRNP H (χ2=17.3, p=0.0001) and a-
rafwt (χ2=24.1, p=0.0001) in tumours while at the same time showing a significant
downregulation of a-rafshort (χ2=7.0, p=0.008).
Comparing the relative expression in normal and tumour tissues (Fig. 6B, Table 1) we found
that in tumour tissues the expression of c-myc (2.5-fold), hnRNP H (1.9-fold), and a-rafWT
(1.3-fold) was significantly higher than in normal tissues. In contrast, a-rafshort expression in
tumours was significantly downregulated compared to normal tissues (1.6-fold decrease).
Pearson’s correlation (Fig. 6C) showed a significant correlation between c-myc/hnrnph
(rp=0.8; p<0.001) and hnrnph/a-rafwt (rp=0.7; p<0.009).
Additionally, we assessed endogenous mRNA expression levels of c-myc and a-rafshort in a
series of 29 human Dukes B colon carcinomas and autologous adjacent non-malignant
tissues by semi-quantitative RT-PCR (Fig. 6B, Table 1). Similar to the results observed in
head and neck carcinomas, at the single-patient level a median relative overexpression of
6.4-fold for c-myc and 0.85-fold for a-rafshort was observed in tumour specimens.
Furthermore, comparing the relative expression in normal and tumour tissues, c-myc
expression was significantly higher in tumours than in normal tissue. In contrast, a-rafshort
expression was significantly downregulated in tumours compared to normal. Importantly,
we observe similar trends in the corresponding A-Raf protein isoform levels, in a limited
number of autologous tissue samples from head and neck carcinomas (n=3). While A-
Rafshort protein is downregulated in carcinomas by trend (p=0.08), expression of A-Rafwt
prevails in carcinomas (p=0.02) (Fig. S6).
The other two human A-Raf isoforms, daRaf1 and daRaf2, were found to be barely
detectable at the mRNA level in the human tissues investigated (semi-quantitative RT-PCR,
1/89 samples, data not shown). Expression of these isoforms was only investigated in mouse
tissues and their expression/regulation in human tissues is not known.
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Discussion
Alternative splicing occurs in more than 90% of genes (36), and is considered as a key
regulatory process by which a common pre-mRNA transcript leads to different mature
RNAs, thus producing diverse and even antagonistic functions (37). This greatly expands
information content and versatility of the transcriptome generating tissue, stage, and
development specific gene expression patterns (38). Tumour suppressors are often
inactivated by splicing in cancer, whereas oncogenes are inactivated by alternative splicing
during normal differentiation (39, 40). Components of the splicing machinery, such as
hnRNP proteins and other RNA binding proteins, have been found altered in tumours and
can contribute to cancer cell survival and invasiveness (41).
We showed previously that the splicing factor hnRNP H is overexpressed in colon and head
and neck cancers, and promotes the correct splicing of the a-raf mRNA that encodes the
wildtype full-length A-Raf protein, which binds to and inhibits the pro-apoptotic kinase
MST2 (6). In this previous work we also showed that overexpression of A-RafWT can
overcome the effects of siRNA-mediated knockdown of hnRNP H. hnRNP H can regulate
alternative splicing of Bcl-X (42) and a neuron-specific variant of Src (43). In both cases,
hnRNP H binds to G-rich RNA stretches (44), similar to sequences found in the intron
sequences included in A-Rafshort. Although hnRNP H favours the production of the pro-
apoptotic Bcl-Xs isoform (42), this splicing event does not prevent the A-Raf mediated
rescue from apoptosis resulting from hnRNP H overexpression (6).
A-Rafshort differs from DA-Raf1 and 2, which encompasses the uninterrupted RBD and
adjacent cysteine rich domain. DA-Raf1 and 2 were not expressed in head and neck tissues
and in human colon specimens except for one out of 89 samples (data not shown). This fits
the current understanding of alternative splicing as usually only two isoforms of a given
number of potential isoforms are predominant at the same time in a given tissue (36). Intron
inclusion is a rare event in alternative splicing (36) and, in combination with pre-terminal
stop codons, these transcripts are commonly prone to nonsense-mediated decay (32).
However, sequence-specific Northern blotting showed that a-rafshort mRNA exists in normal
human tissues such as brain, placenta, kidney, pancreas, lung, and spleen (data not shown).
The resulting A-Rafshort protein is expressed both in cultured cells and in human tissues at
low but stable levels, which is consistent with recent findings that such pre-terminated
mRNAs typically express low levels of protein (45).
Functionally, A-Rafshort inhibits ERK pathway activation by competing for binding to
activated Ras. This was un-expected, as intron 2 is inserted into the RBD between glutamine
29 (66 in Raf-1) and lysine 47 (84 in Raf-1), which together with arginine 52 (89 in Raf-1)
form a functional epitope in Raf-1 that determines the affinity to Ras (46). However, the
binding of A-Rafshort to Ras was GTP dependent and of similar affinity as full-length A-Raf,
suggesting a functionally relevant interaction. The functionality of this interaction was
corroborated by the finding that A-Rafshort behaved as a dominant negative mutant, which
suppressed Ras mediated transformation and ERK activation. In contrast, A-Rafshort cannot
bind to and inhibit MST2 pro-apoptotic signalling. Our finding that the expression of A-
Rafshort is reduced in cancers correlating with the overexpression of hnRNP H and increased
expression of full-length A-Raf protein also suggest that alternative a-raf splicing is a
pathophysiological mechanism that tumours use to evade apoptosis.
We show that one mechanism regulating hnRNP H levels is via the proto-oncogene c-Myc.
As suggested by data from the ENCODE project (31) we show that c-Myc binds directly to
a non-canonical E-box in the hnRNP H1 gene promoter in a mitogen-dependent way.
Knockdown of c-Myc decreased levels of hnRNP H and subsequent A-Rafshort splice form
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selection. Activation of c-Myc had the opposite effect. Interestingly, c-Myc also stimulates
the expression of other members of the hnRNP family, hnRNP A1, hnRNP A2, and hnRNP
I (47). These hnRNP proteins promote the alternative splicing of pyruvate kinase resulting in
the expression of the embryonic isoform, PKM2, which is almost universally re-expressed in
cancer, and stimulates aerobic glycolysis (48). Thus, c-Myc can regulate two splice events
via hnRNP proteins that enhance survival via A-Raf mediated MST2 inhibition and switch
metabolism to the aerobic glycolysis typical for cancer cells. Additional crosstalk between
these two pathways may exist at the protein level as A-Raf was reported to bind to and
regulate PKM2 function (49).
In summary, we propose the following working hypothesis (Fig. 6D): In tumour cells high
levels of c-Myc elevate expression of the splice factor hnRNP H shifting the balance of a-raf
mRNA splicing in favour of producing the full-length A-Raf protein, which is crucial to
keep pro-apoptotic MST2 signalling in check. In normal cells c-Myc levels are low,
resulting in reduced hnRNP H expression and a shift of a-raf splicing towards A-Rafshort
with the dual effect of relieving repression of MST2 and reducing ERK pathway activity due
to Ras blockade by A-Rafshort.
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Figure 1: The A-Rafshort isoform expression is induced after hnRNP H knockdown.
(A) a-rafshort, a-rafWT/short, and hnRNP H mRNA expression in HeLa cells was analyzed by
RT-PCR after transfection with control or hnRNP H-specific siRNA (siRNA#1). Shown is a
representative result from two independent experiments. (B) A-Rafshort, A-RafWT, and
hnRNP H protein expression was analysed by immunoblotting after transfection with control
or hnRNP H-specific siRNA (siRNA#1). As a positive control for A-Rafshort, a lysate
containing transfected recombinant HA-tagged A-Rafshort was used. Shown are the
representative results from two independent experiments. (C) Pre-adsorption of polyclonal
A-Raf antibodies with peptides used for immunisation abrogated binding of A-Raf but
not HA-specific antibody. Increasing concentrations of HA-tagged A-Rafshort was
expressed in HeLa and analysed by immunoblotting using HA- or A-Raf N-terminus
specific antibodies. The A-Raf N-terminus specific antibody but not the HA-antibody signal
was blocked by adding the A-Raf N-terminal peptide as competitor, showing that the
detection of the A-Rafshort isoform to be specific. Shown are the representative results from
two independent experiments.
Rauch et al. Page 11
Cancer Res. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2: The A-Rafshort protein does not interact with MST2.
(A) Flag-tagged MST2 together with HA-tagged A-Rafwt or A-Rafshort, respectively, were
expressed in HeLa cells. MST2 and A-Raf isoforms were immunoprecipitated (IP) using
flag-tag specific antibodies. Flag-MST2 and A-Rafwt, but not the short isoform A-Rafshort,
co-precipitated as shown by immunoblotting (WB). Shown are the representative results
from three independent experiments. (B) HA-tagged A-Rafwt or A-Rafshort were expressed
in HeLa cells. Endogenous MST2 and the HA-tagged A-Raf isoforms were
immunoprecipitated (IP) with HA-tag or MST2 specific antibodies. MST2 and A-Rafwt, but
not A-Rafshort, co-precipitated. Shown are the representative results from three independent
experiments. (C) A-Rafwt but not A-Rafshort can suppress MST2 kinase activity. HeLa
cells were transfected with hnRNP H (siRNA#1) and control siRNA. Where indicated, HA-
A-Rafwt, HA-A-Rafshort, or control expression plasmids were co-transfected. MST2 kinase
activity was assessed by in-gel kinase assays. (D) A-Rafwt but not A-Rafshort can suppress
apoptosis induced by hnRNP H depletion. Apoptosis was determined in HeLa cells
following transfection with hnRNP H-siRNA. Where indicated, cells were co-transfected
with A-Rafwt, A-Rafshort expression plasmids. The data represent mean percentage of
apoptosis with SD of three experiments. Additionally, cells were lysed, and expression of
flag-tagged A-Raf, Caspase-3, and PARP was assessed by immunoblotting (lower panels).
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Figure 3: A-Rafshort inhibits Ras-ERK signalling.
(A) Numbers of HeLa, GHD-1, and HCT-116 cells were determined in a time kinetic
following overexpresion of A-Rafshort or A-RafWT. Results represent the mean with
standard deviation (SD) of three independent experiments. (B) A-Rafshort inhibits
phosphorylation of ERK. Hela cells were transfected with increasing amounts of A-
Rafshort or A-RafWT. Cells were serum-starved for 16 hours (0.1% FCS) or serum-
stimulated (10% FCS) for 5min after starvation as indicated. Lysates were immunoblotted
for expression of the transfected flag-tagged Raf isoforms, phopho-ERK1/2, and ERK1/2 as
loading control. (C) A-Rafshort inhibits ERK phosphorylation without affecting AKT
phosphorylation. Hela cells were transfected with either A-Rafshort or A-RafWT. Cells were
serum-starved for 16 hours (0.1% FCS) or serum-stimulated (10% FCS) for 5min after
starvation as indicated. Lysates were immunoblotted for expression of the transfected flag-
tagged Raf isoforms, phopho-ERK1/2, ERK1/2, phospho-AKT, and AKT. (D) A-Rafshort
siRNA#3 specifically downregulates the A-Rafshort isoform and increases ERK
phosphorylation. (left panel) Hela cells were transfected with four different siRNAs for A-
Rafshort or A-RafWT. Cells were serum-starved for 16 hours and serum-stimulated for 5min.
Lysates were immunoblotted for expression of A-Rafshort, A-RafWT, phopho-ERK1/2, and
ERK1/2. Shown are the representative results from two independent experiments. (right
panel) Hela cells were transfected with either A-Rafshort siRNA#3 or control siRNA. Cells
were serum-starved for 16 hours (0.1% FCS) or serum-stimulated (10% FCS) for 5min after
starvation as indicated. Lysates were immunoblotted for expression of A-Rafshort, phopho-
ERK1/2, and ERK1/2.
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Figure 4: A-Rafshort interacts with activated Ras inhibiting Ras-ERK signalling.
(A) Flag-tagged A-Rafshort or A-RafWT were transfected in HeLa cells. Cells were serum-
starved for 16 hours (0.1% FCS) or serum-stimulated (10% FCS) for 5min after starvation as
indicated. A-Raf isoforms were immunoprecipitated with flag-tag specific antibodies, and
analysed by immunoblotting for the interaction with Ras. (B) Endogenous Ras was
immunoprecipitated from lysates of HeLa cells, which had been serum starved (0.1% FCS,
16 hours) or treated with full medium (10% FCS) after serum-starvation using a specifc
antibody for Ras, and analysed by immunoblotting (upper panel). As an isotype control, an
antibody specific for GFP was used (middle panel, ‘Isotype’). Lysates were immunoblotted
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for expression of A-Rafshort, Ras, B-Raf, phosphorylated ERK1/2, and ERK1/2 as loading
control (lower panel). LC - light chain immunoglobulin. Shown are the representative results
from three independent experiments. (C) A-Rafshort binds better to Ras. Either fixed or
increasing amounts of Flag-tagged A-Rafshort or A-RafWT togther with HA-tagged H-Ras-
V12 were transfected in HeLa cells as indicated. Cells were serum-starved for 16 hours
(0.1% FCS) and serum-stimulated (10% FCS) for 5min after starvation. Ras complexes were
immunoprecipitated, and analysed by immunoblotting for the A-Raf isoform interaction. (D)
A-Rafshort inhibits Ras-induced cellular tranformation. NIH3T3 fibroblasts were
tranfected with hyperactive Ras constructs. Cells were co-tranfected with either A-RafWT or
A-Rafshort as indicated (left panel). Numbers indicate average number of foci per microgram
of DNA (Ras constructs) (right panel). Error bars represent standard deviation of at least
three independent experiments.
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Figure 5: c-Myc regulates hnRNP H expression.
(A) Hela cells were transfected with either c-myc siRNA or control siRNA. Lysates were
immunoblotted for expression of c-Myc, hnRNP H, A-RafWT or A-Rafshort, and ERK1/2
using specific antibodies. (B) HeLa cells were transfected with the 4-hydroxytamoxifen (4-
OHT)-inducible chimeric MycERT, hnRNP H siRNA, or Control siRNA as indicated.
Following transfection, cells were serum-starved for 16 hours (0.1% FCS) and MycERT
induced with 4-OHT (100nM). 0, 4, and 8 hours post induction, cells were lysed and lysates
immunoblotted for expression of the hnRNP H, A-RafWT or A-Rafshort, and ERK1/2 as
loading control. (C) HeLa cells were serum-starved for 18 hours (0.1% FCS) and stimulated
with EGF (10nM) as indicated. 5, 30, 60, 180, and 360min post stimulation, cells were lysed
and lysates immunoblotted for expression of the c-Myc, hnRNP H, A-RafWT, A-Rafshort,
phopho-ERK1/2, and ERK1/2 as loading control. (D) c-Myc binds to promotor elements
of the human HNRNPH1 genomic locus. c-Myc Chromatin IPs in either serum-starved
(18hrs, 0.1% FCS) or EGF-stimulated Hela cells were analyzed using semi-quantitative
Real-time PCR. PCR primer pairs correspond to elements in the human hnRNP H promotor
region as depicted. The red line indicates no change in c-Myc-specific enrichment. Shown
are the representative results from three independent experiments, error bars represent
standard deviations.
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Figure 6: Expression of c-myc, hnRNP H, and a-raf isoforms in carcinomas and adjacent normal
tissues.
(A) The expression of a-rafshort, a-rafWT, hnRNP H, and c-myc mRNA was assessed in head
and neck (HNSCC) tumours (T) and normal adjacent tissues (N) by semi-quantitative RT-
PCR. Mapk1 mRNA levels were determined as a loading control. (B) Relative expression of
c-myc, hnRNP H and a-raf isoforms in head and neck tissues (left panel) and in colon
carcinomas (n=29) and adjacent normal tissues (n=29) (right panel) according to disease
state. Shown are boxplots where boxes indicate the median (line) and IQR, whiskers show
the range, and asterisks indicate outliers. (C) Scatterplots are used to illustrate the degree of
correlation between c-myc/hnRNPH, hnRNP H/a-rafWT, and hnRNPH/a-rafshort relative
expression in tumours (red) and normal tissues (blue). (D) Hypothesis and model for
hnRNP H-mediated A-Raf isoform selection. In normal cells, low levels of the proto-
oncogene c-Myc and the splice factor hnRNP H ensure increased A-Rafshort levels thus
keeping proliferation via MAPK signalling in check. Tumour cells show higher expression
of both c-Myc and hnRNP H thereby enabling sufficient A-RafWT expression and keeping
MST-2 mediated apoptosis in check. Additionally, A-Rafshort is downregulated in tumour
cells enabling increased proliferation.
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